Plain-English translation of NCT06749457 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new medication called to see if it can help prevent a serious bacterial infection (caused by Staphylococcus aureus) in people with end-stage kidney disease who receive hemodialysis. The trial has two parts: first, healthy adults will receive a single dose to check that the medication is safe and how the body processes it; then, people on dialysis will receive two doses, three months apart, to see if the treatment prevents infections and remains safe in their group.
People on dialysis are at high risk for serious bacterial infections, which can be life-threatening and difficult to treat. This medication is being tested to see whether it could prevent these infections and improve outcomes for dialysis patients.
You likely qualify if…
You likely don't qualify if…
If you are in the first part of the study (healthy adults), you will visit the clinic once to receive a single intravenous infusion and then return for follow-up visits over 12 months. If you are in the second part (dialysis patients), you will receive two intravenous infusions three months apart, with follow-up clinic visits for 12 months after your last dose. All participants will have blood tests and health checks during screening and follow-up to monitor for any side effects.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
United States